CN1182370A - 含有皂苷和固醇的疫苗 - Google Patents

含有皂苷和固醇的疫苗 Download PDF

Info

Publication number
CN1182370A
CN1182370A CN96193443A CN96193443A CN1182370A CN 1182370 A CN1182370 A CN 1182370A CN 96193443 A CN96193443 A CN 96193443A CN 96193443 A CN96193443 A CN 96193443A CN 1182370 A CN1182370 A CN 1182370A
Authority
CN
China
Prior art keywords
antigen
vaccine
cholesterol
virus
mpl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN96193443A
Other languages
English (en)
Other versions
CN1111071C (zh
Inventor
纳撒利·M-J·C·加肯
马丁·弗里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1182370(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9508326.7A external-priority patent/GB9508326D0/en
Priority claimed from GBGB9513107.4A external-priority patent/GB9513107D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of CN1182370A publication Critical patent/CN1182370A/zh
Application granted granted Critical
Publication of CN1111071C publication Critical patent/CN1111071C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及一种含有抗原,免疫活性的皂苷组分以及固醇的疫苗组合物。

Description

含有皂苷和固醇的疫苗
本发明涉及新的疫苗配方及其制备方法和在医学中的应用。本发明特别涉及那些含有一种抗原，一种来源于Quillaja Saponaria Molina树皮的免疫活性组分如QS21，以及一种固醇的疫苗。
来源于南美洲的Quillaja Saponaria Molina树皮的免疫活性的皂苷组分具有佐剂的活性是本领域内众所周知的。比如QS21(也称为QA21)，一种HPLC纯化的来源于Quillaja Saponaria Molina树的组分及其制备方法公开于(作为QA21)美国专利5,057,540中。皂树皮皂苷作为佐剂也已由Scott等人披露(Int.Archs.Allergy Appl.Immun.，1985，77，409)。然而，QS21用作佐剂却伴随着某些缺憾。例如，将QS21作为游离分子注射入哺乳动物时，可以发现坏死，也就是说在注射部位发生了局部组织坏死。
现已意外地发出那种在注射部位的坏死可以通过使用含有QS21和固醇相组合的配方而得以避免。优选的固醇包括β-谷固醇，豆固醇，麦角固醇，麦角钙化(固)醇和胆固醇。这些固醇是本领域内众所周知的，比如胆固醇作为一种天然的发现于动物脂肪的固醇见于默克索引(Merck Index)，第11版，341页。
因此，本发明的第一个方面是提供一种含有抗原，免疫活性的皂苷组分和固醇的疫苗组合物。本发明的组合物优选地含有大体上纯的免疫活性皂苷组分。本发明的组合物优选地含有大体上纯的QS21，也就是说该QS21是至少90％纯的，优选地是95％纯的而最优选地是98％纯的。其它在本发明的组合物中有用的免疫活性皂苷组分包括QA17/QS17。含有QS21和胆固醇的本发明组合物相比于无胆固醇的组合物表现出了降低的反应原性，而其佐剂的效果却不变。此外，已知该QS21在pH约为7或更高的碱性环境中降解。本发明还有一个优越性是QS21在含有胆固醇的配方中对碱介导的水解的稳定性增强。
本发明优选的组合物是那些形成了脂质体结构的。那些其中的固醇/免疫活性的皂苷组分形成了ISCOM结构的组合物也构成了本发明的一个方面。
QS21∶固醇的比率通常为大约1∶100到1∶1的重量比(W/W)。固醇优选地以过量存在，而QS21∶固醇的比率至少为1∶2W/W。用于对人类给药的疫苗中，QS21和固醇通常是以每剂量大约1微克到100微克的范围，优选地为大约10微克到50微克的范围存在。
该脂质体优选地含有中性脂，如磷脂酰胆碱，其优选地在室温下是非晶态的，如蛋黄磷脂酰胆碱，二油酰磷脂酰胆碱或二月桂酰磷脂酰胆碱。该脂质体也可以含有带电的脂质，其能提高脂质体-QS21结构(其中的脂质体是由饱和脂所构成的)的稳定性。在这些情况下，该带电的脂质的量优选地为1-20％W/W，最优选地为5-10％。固醇对磷脂的比率为1-50％(mol/mol)，最优选地为20-25％。
本发明的组合物优选地含有MPL(3-脱酰单-磷酰类脂A，也称作3D-MPL)。而作为3种脱-氧-酰化的单磷酰类脂A和4，5或6酰化的链的混合物的3D-MPL见于GB 2220211(Ribi)中并由蒙大拿的Ribi免疫化学公司制备。国际专利申请92/116556公开了一个优选的存在形式。
本发明的合适的组合物是那些其中的脂质体最初是在无MPL下制备，然后，再加入，优选地为100nm的颗粒的MPL。因此，该MPL没有包含在囊泡膜内(称为MPL外)。而那些其中的MPL包含在囊泡膜内的组合物(称为MPL内)也构成了本发明的一个方面。该抗原可以包含于囊泡膜内或外。优选地，可溶性抗原是包含于膜外的而疏水性的或者脂化的抗原则既可以包括于膜外又可以包括于膜内。
本发明的疫苗通常无需任何特殊的载体而可以在水或者其它的药物可接受的缓冲液中配制。在某些情况下可能有益的是本发明的疫苗还可以含有明矾或者存在于水包油的乳剂中，或者其它合适的赋形剂内，如脂质体，微球体或者微囊化的抗原颗粒。
该疫苗配方优选地含有一种能够诱发可以抵抗人类或者动物病原体的免疫反应的抗原或者抗原组合物。在本领域已知的抗原或者抗原组合物可以用于本发明的组合物中，其包括多糖类抗原，源于HIV-1的(如gP120或gP160)，任何猫科动物免疫缺陷病毒，人或动物疮疹病毒，如gD或其衍生物或源于HSVI1或HSV2的直接早期蛋白如ICP27，巨细胞病毒(特别是人)(如gB或其衍生物)，水痘带状疱疹病毒(如gPI，II或III)的抗原或者抗原组合物，或者源于诸如乙肝病毒的肝炎病毒的抗原如乙肝表面抗原或其衍生的甲肝病毒，丙肝病毒和戊肝病毒的抗原或者抗原组合物，或者来源于其它病毒性致病原的抗原，如呼吸道合胞病素(如美国专利5,149,650中公开的HSRVF和G蛋白或其免疫片段或者美国专利5,194,595中公开的含有来源于HSRV蛋白F和G的免疫片段的嵌合多肽，如FG糖蛋白)，来源于脑膜炎菌株如甲，乙和丙型脑膜炎，肺炎链球菌，人乳头瘤病毒，流感病毒，B型流感嗜血杆菌(Hib)，EB病毒(EBV)的抗原，或者来源于细菌性病原如沙门氏菌，疏螺旋体属(例如OspA或OspB或其衍生物)，或者衣原体属，或者博代杆菌属如P.69，PT和FHA的抗原，或者来源于寄生虫如疟原虫属或弓形虫属的抗原。
HSV糖白D(gD)或衍生物是优选的疫苗抗原。其位于病毒膜上，并且也见于感染的细胞的胞质中(Eisenberg R.J.等人；病毒学杂志1980 35 428-435)。其含有包括一个信号肽的393个氨基酸且分子量约为60KD。它可能是所有HSV被膜糖蛋白中特性最优者(Cohen等人，病毒学杂志60 157-166)。已知其在体内对病毒吸附于细胞膜起着重要的作用。此外，糖蛋白D在体内已表现出能诱发中和抗体并防止动物受致命的攻击。平头型的gD分子没有C末端锚形区且能够以可溶蛋白形式在哺乳动物细胞内产生，然后再分泌到该细胞培养的上清液中。该可溶型的gD是优选的。平头型的gD分子的生产见于EP 0139417中。该gD优选地来源于HSV-2。本发明的一个实施例是308个氨基酸平头型HSV-2糖蛋白D，其含有天然糖蛋白中的氨基酸1-306，并在无膜锚形区的平头型蛋白的C末端加入天冬酰胺和谷氨酰胺。此类蛋白包括信号肽，而信号肽裂解后便于该成熟的含有283氨基酸的可溶蛋白从宿主细胞中分泌出来。
在本发明的另一方面，乙肝表面抗原是优选的疫苗抗原。
这里用的“乙肝表面抗原”或者‘HBsAg’一词包括任何HBsAg抗原或其表现出HBV表面抗原的抗原性的片段。可以理解的是，除了该HBsAg抗原的226个氨基酸(见于Tiollais等人，自然，317，489(1985)及其中的参考文献)外，若需要，这里所述的HBsAg可以包括全部的或者部分的上述参考文献及EP-A-0278940中所述的一种前-S序列。特别地，该HBsAg可以包括含有一种氨基酸序列的多肽，该氨基酸序列先后分别包括对应于一种近血清型的乙肝病毒的开放阅读框的HBsAg的L-蛋白的12-52残基、133-145残基、175-400残基(此多肽是指L*；见于EP 0414374)。在本发明的范围内的HBsAg还可以含有EP 0198474(Endotronics)中所述的前-S1-前S2-S多肽或者其严格的如EP 0304578(Mc Cormick和Jones)中所述的类似物。这里所述的HBsAg还能指突变体，比如WO 91/14703或欧洲专利申请0511855 A1中所述‘逃避突变体’，尤其指在其中的145位氨基酸处由精氨酸取代了甘氨酸的HBsAg。
该HBsAg一般是微粒型的。该微粒可以单独含有诸如S蛋白或者是组合微粒，如(L*，S)，其中的L*如上文定义而S则指HBsAg的S-蛋白。该微粒最好是以在酵母中表达的形式。
乙肝表面抗原S-蛋白的制备是有充分的文献报道的。例如见于Harford等人(1983)，发育生物学规范(Develop.Biol.Standard)54，125页，Gregz等人(1987)，生物技术，5，479页，EP 0226846，EP 0299108及其中的参考文献。
在本发明的范围内的配方还可以含有抗-肿瘤抗原并用于肿瘤的免疫治疗。
通常，疫苗的制备见于Vbller等人编辑的疫苗新趋势和进展(Park大学出版社，巴尔的摩，马里兰州，美国，1978)。在脂质体中成囊见于诸如Fullerton，美国专利4,235,877中。和蛋白质结合成大分子则公开于诸如Lkhite，美国专利4,372,945和Armor等人的美国专利4,474,757。
将每个疫苗剂量中的蛋白量定为能在常规疫苗中诱发免疫保护反应却不引起明显的副作用的量。此量的变化依赖于使用的具体免疫原以及其存在形式。一般地，所期望的是每个剂量中包含有1-1000微克蛋白，优选地为2-100微克，最优选地为4-40微克。微粒疫苗的最佳量可以通过包括检测实验对象的合适的免疫反应在内的常规研究而确定。初次接种后，受试对象还可以在充分的时间间隔后再接受一次或者几次加强接种。
本发明的配方既可用于预防，又可用于治疗目的。
相应地，本发明还有一个方面就是提供了本发明的疫苗的治疗病人的应用。本发明提供了一个包括对病人给于有效剂量的本发明的疫苗的治疗方法。本发明尤其是提供了一个包括对病人给于有效剂量的本发明的疫苗从而治疗病毒性的，细菌性的，寄生虫性的感染或者肿瘤的方法。
下列实施例和数据阐明了本发明。
实施例1.1制备脂质体的方法
将置于有机溶剂中的脂质(如来源于蛋黄的或者合成的磷脂酰胆碱)和胆固醇的混合物在真空(或者惰性气流)下干燥。然后，加入一种水溶液(如磷酸盐缓冲液)，振荡该容器直止脂质全部进入悬浊液中。然后，将该悬浊液微观流化直止该脂质体大小降至100nm，再通过0.2μm的滤器进行无菌过滤。挤压和声处理可以代替该步骤。该胆固醇，磷脂酰胆碱的常规比率是1∶4(W/W)，而加入的水溶液使胆固醇的终浓度为5-50mg/ml。如果将置于有机溶液的MPL加入溶于有机溶液的脂质内，那么最终的脂质体含有的MPL在膜内(指MPL内)。
将该脂质体的大小规定为100nm并且是指SUV(小单室囊泡)。如果反复冻融该溶液，那么囊泡融合成大小为500nm至15μm的大的多室结构。该脂质体本身是可以长期稳定的且没有致融能力。1.2配制步骤
将QS21水溶液加入该脂质体中。然后，将该混合物加入到抗原溶液中，并且若需要，还可以含有呈100nm微粒状的MPL。1.3含有胆固醇的脂质体抑制QS21的溶解活性
当QS21加入到红细胞中时可以溶解红细胞使其释放血红蛋白。该溶解活性也可以使用含有存在于膜内的胆固醇以及捕获的荧光染料，羧荧光素的脂质体进行检测  当该脂质体被溶解时便释放染料，而该染料又可用荧光分光镜进行检测。若在荧光脂质体的膜内不含胆固醇，那么不会观察到溶解作用。
若在加入到红细胞中之前，将该QS21和含有胆固醇的脂质体共同培育，那么该红细胞的溶解依赖于胆固醇对QS21的比率而降低。若使用的比率为1∶1，则没有检测到溶解活性。如果该脂质体不含胆固醇，则抑制溶解需要比QS21过量1000倍的磷脂。
用荧光脂质体检测溶解活性同样有效。在下图中，通过荧光检测了用无胆固醇(1mg/ml蛋黄磷脂酰胆碱)或含有胆固醇(1mg/ml磷脂酰胆碱，500μg胆固醇)的脂质体处理的4μgQS21的溶解活性。
数据显示QS21在膜内以特定的方式和胆固醇结合，从而引起溶解(细胞的或者荧光脂质体的)。如果QS21首先和脂质体中的胆固醇结合，那么不再溶解细胞或其它脂质体。这要求胆固醇∶QS21(W/W)的最低比率为0.5∶1。
胆固醇在水溶液中不溶且也不能形成稳定的悬浊液。当有磷脂存在时，该胆固醇存在于磷脂双分子层中并能形成称为脂质体的稳定的囊泡悬浊液。为了避免需要加入磷脂而试验了一个可溶的衍生物。聚氧乙烷胆固醇癸二酸盐在水中的溶解能力达到60mg/ml，然而，既使使用超过QS21 2000倍的量，也没有检测到QS21溶解活性的降低。1.4含有胆固醇的脂质体增加了QS21的稳定性
QS21在pH约为7的环境中极易水解。该水解作用可以在反相HPLC上通过检测对应于QS21的峰的降低而测定。例如，下图表明在pH9的37℃下，16小时内有90％的QS21被水解。如果在该QS21中以2∶1的比率(胆固醇：QS21 W/W)加入含有胆固醇的脂质体，则在同样的条件下没有检测到水解作用。若比率为1∶1，则有10％的QS21被降解。
将20μgQS21在含胆固醇的SUV存在且pH9，37℃下培育16小时
Figure A9619344300091
可以得出结论的是，当QS21和含有胆固醇的脂质体结合时，其变得极不易受碱介导的水解作用。据报道，该水解产物经注射给药，无佐剂活性，因而，含有QS21的疫苗必需在酸性pH中配制并保藏在4℃以维持佐剂组合物。使用脂质体可以避免该项要求。1.5反应原性研究：
在小鼠胫骨肌注射5μgQS21(或者洋地黄皂苷)和逐步增加量的脂质体(以胆固醇的μg表示)。溶解活性表示为相当于QS21量(μg)，其含义是要达到样品中同样的溶血作用所需的QS21的量。
处死动物后，目测评分注射位点的肌肉的充血，坏死和毒性状况。
    配方     水解活性μg   充血   坏死   毒性
QS21+PBS  5 +++ ± +++
QS21+1μg胆固醇(SUV)  4 +++ + ++++
QS21+5μg胆固醇(SUV)  0  - - ±
QS21+25μg胆固醇SUV  0 ± - +
单独SUV  0 - - -
洋地黄皂苷  5 - - ±
PBS  0 - - -
数据显示当溶解活性由于含有胆固醇的脂质体的加入而消除后，源于QS21的毒性也随之消除。1.6免肌内反应原性
U.I./L值
    实验     配方 第0天 溶血作用   第1天 溶血作用 第3天 溶血作用
    兔n°1兔n°2兔n°3兔n°4兔n°5 QS21 50μg   107811166605923400     ±   86504648481956627528   152314356846841736
均值SD  13691160   62611757   1212495
  实验   配方 第0天 溶血作用 第1天 溶血作用   第3天 溶血作用
    兔n°6兔n°7兔n°8兔n°9兔n°10 QS21 50μgSUV内的胆固醇50μg(1∶1)   5965406115211092 ±     16706021873507787     460594803616555
均值SD   672238     1088636     606125
    实验     配方 第0天 溶血作用 第1天 溶血作用   第3天 溶血作用
    兔n°11兔n°12兔n°13兔n°14兔n°15 QS21 50μgSUV内的胆固醇150μg(1∶3)   3328314645281027   344662356720568   387694519614849
均值SD    637285     530173   613175
    实验     配方 第0天 溶血作用 第1天 溶血作用   第3天 溶血作用
    兔n°16兔n°17兔n°18兔n°19兔n°20 QS21 50μgSUV内的胆固醇250μg(1∶5)   5404984428223182 ±     7694047178012410     745471(4535)925960
均值SD   10971175     1020793     775224 (1527)(1692)
    实验     配方 第0天 溶血作用 第1天 溶血作用   第3天 溶血作用
    兔n°21兔n°22兔n°23兔n°24兔n°25 PBS   3216606501395429 ±     290535603(3545)323     378755473(5749)263
均值SD   691419     438155 (1059)(1396)     467210 (1523)(2369)
数据显示在配方中加入含有胆固醇的脂质体可以显著地降低QS21所致的CPK(肌酸磷酸激酶)升高。由于CPK的升高是肌肉损伤的量度，所以其意味着肌肉损伤的降低且已经组织病毒学证实。1.7脂质体-QS21的复合物和明矾相结合。
将QS21和含有过量的胆固醇以及放射性胆固醇的中性脂质体一起培育，然后，再和溶于PBS中的明矾(Al(OH)3)一起培育。单独的中性脂质体和QS21都不能和溶于PBS的明矾相结合，而带有负电荷的脂质体也不能。然而，当QS21和中性脂质体一起都可以和明矾相结合。该上清液既不含QS21(苔黑酚试验检测)也不含放射性胆固醇。
这表明QS21已结合于脂质体且允许该脂质体-QS21结合物结合于明矾。这可能产生于由QS21加于该脂质体的负电荷，或者脂质体上的疏水区的暴露。该结果也意味着QS21不能从膜中抽提胆固醇。
这表明本发明的组合物可用于基于明矾的疫苗中。1.8脂质体样QS21/MPL和游离QS21+MPL的抗体及CMI诱发的比较
用挤压技术制备SUV(EYPC∶胆固醇∶MPL 20∶5∶1)。
对MPL外而言，脂质体在无MPL的条件下制备并再以100nm的微粒态加入MPL。
QS21先于抗原加入。胆固醇∶QS21＝5∶1(W/W)
在抗原加入前，通过3次冻融SUV制备MLV。
对捕获抗原而言，抗原在冻融前加入到SUV中并在冻融后加入QS21。抗原成囊＝5％内，95％外。在小鼠(gD用balb/c，RTSs用BIOBR)的足垫处注射两次。gD是来源于单疱疹病毒的糖蛋白。RTSs是指经过遗传改良而含有一个来源于原生团恶性子孢子的抗原表位的乙肝表面抗原(HBsAg)。
ag＝10μgRTSs     强化后15天的抗HBsAg滴度
    配方  IgG1   IgG2a  IgG2b
 SUV/QS+MPL(外)       +Ag  1175   10114  71753
 MLV/QS+MPL(外)       +Ag  2247   11170  41755
 MLV/QS/MPL(内)       +Ag   969    7073  18827
 MLV/QS/MPL(内)/Ag(内)+Ag   1812    2853   9393
    QS+MPL            +Ag   372    9294  44457
                       Ag  ＜100   ＜100  ＜100
 SUV/QS+MPL(外)  ＜100   ＜100  ＜100
 MLV/QS/MPL(内)  ＜100   ＜100  ＜100
 ag＝20μggD 抗gD     CMI
    配方 IgG IFN-γ96小时(pg/ml) IL248小时pg/ml
 SUV/QS+MPL(外)       +Ag  2347  1572  960
 SUV/QS/MPL(内)       +Ag  2036  1113  15
 MLV/OS+MPL(外)       +Ag  1578  863  15
 MLV/QS/MPL(内)       +Ag  676  373  15
 MLV/QS/MPI(内)/Ag(内)+Ag  1064  715  15
    QS+MPL            +Ag  1177  764  15
                       Ag ＜100  567  44
 SUV/QS+MPL(外) ＜100  181  15
 MLV/QS/MPL(内) ＜100  814  105
数据显示：SUV/QS+MPL(外)诱导出至少和QS21+MPL相当的高抗体滴度，以及诱导出作为细胞介导免疫标记的IL-2，而抑制QS21的反应原性。
另外，用HSV gD作抗原在balb/c小鼠中对比QS21和有胆固醇(SUV)存在的QS21第二个实验的结果如下：
II后第7天同模标本
  配方SUV/QS21+MPL外SUV/QS21/MPL内QS21+MPLSUV/QS21+MPL外QS21SUV/QS21   抗原gD(5μg)gD(5μg)gD(5μg)无gD(5μg)gD(5μg) II后第7天IgG(GMT) II后第14天IgG(GMT) IgGlμg/ml ％ IgG2aμg/ml ％ IgG2bμg/ml    ％
    2029012566105040346811253     1634310731101680413211589     3314182000156484  26443406657     716412285067304  56444802836     222   17111   12107   180    014    665    8
1.9比较分别加上脂质体样的MPL/QS21和游离的MPL/QS21的gD120
脂质体＝在膜内含MPL的SUV
胆固醇∶QS21＝6∶1
在一次免疫接种后两周检测反应
    配方   增殖 IFN-gng/ml  IL2pg/ml  IL5pg/ml
 SUV/MPL/QS21+Ag   12606   16.6   59   476
     MPL+QS21+Ag   16726   15.8   60   404
第二次免疫接种后：
    配方   增殖 IFN-gpg/ml  IL4pg/ml  IL5pg/ml
 SUV/MPL/QS21+Ag   12606  135   0   250
    MPL+QS21+Ag   16726   60   0   500
数据显示QS21和含有胆固醇的脂质体以及MPL相结合能诱发出相当于MPL+QS21的Th1/Th0反应。
在此胆固醇对QS21的比率下，QS21对兔子无毒性(用CPK作指标)
在第二个试验中，balb/c小鼠用有QS21或者QS21+含有胆固醇的SUV存在的gDI20足垫注射进行免疫。测定了脾细胞中胞毒T淋巴细胞的活性。
Figure A9619344300151
这表明单独的QS21诱发CTL活性，而在有含胆固醇的脂质体存在的情况下的QS21至少能诱发出和单独的QS21相当或者更好的CTL活性。2.疫苗2.1HBsAgL*，S颗粒的配制
HBsAgL*，S颗粒可如下配制：
将10μgHBsAgL*，S颗粒/剂在室温下搅拌培育一小时。用注射用水和PBS溶液调节该体积并最终用QS21(10μg/剂)的水溶液将体积定为70μl/剂。pH维持在7±0.5。
使用1和50μgHBsAgL*，S可制备类似的配方，并且还可以使用HBsAgS抗原。
这些配方可在旱獭替代治疗模型中用旱獭HBV抗原作模型进行检测。旱獭模型
DQQS21(即QS21/胆固醇或抑制的QS21)可在长期注射病毒的旱獭的治疗模型中进行检测。具体的旱獭乙肝病毒疫苗可以和如此的QS21或者DQ混和并且可以带有或者不带MPL，其每月均对动物给药，连续六个月。该疫苗的效应可通过病毒DNA的清除率来评估。2.2豚鼠模型(HSV)2.2.1预防模型
将12只为一组的雌Harttey豚鼠用下述配方在零天和第28天肌内注射：第一次实验：gD5μg+QS21 50μg+含50μg胆固醇的SUVgD5μg+QS21 100μg+含100μg胆固醇的SUVgD5μg+QS21 50μg+含250μg胆固醇的SUVgD5μg+QS21 50μg第二次实验：gD5μg+MPL12.5μg+QS21 12.5μg+含62.5μg胆固醇的SUV，或者不处理。
在第二次免疫接种的第14和28天对动物进行放血，测定血清中gD-特异的ELISA抗体滴度。
然后，用105空斑单位(pfu)的HSV-2MS株阴道注射攻击动物。在第4-12天每天对动物进行初期疱疹损伤评估。得分如下：阴道损伤：-流血＝0.5-充血1或2天但没有流血＝0.5-充血并流血1天＝1-充血但没有流血且持续至少3天＝1外部疱疹水疱：-＜4个小水疱＝2-＞＝4个小水疱或者一个大水疱4＞＝4个大瘤8融合瘤＝16-在全部外生殖区的融合大瘤＝32结果如下表所示：
预防模型
实验1(chol是指含有胆固醇的SUV)
数量     配方                                      初期病变
1211121212 gD/QS21 50μggD/QS21 50μg-chol1/5gD/QS21 50μg-chol1/1gD/QS21 50μg-chol1/1未处理 无损伤的动物百分数(％) 阴道损伤发病率(％) 外部损伤发病率(％) 初期感染系数** 相对于对照组的降低 损伤严重性*中数 数目
    50641005025     33180330     171801775     7367054996     93％93％100％95％-     1.502.50-0.7555.00     64-69
实验2
数量     配方     Ab滴度(GMT)                                     初期病变
1212 gD/QS21/SUV/MPL未处理     ELzSA   中和第二次后28天   无损伤动物％ 阴道损伤发病率％ 外部损伤发病率％ 初次感染系数** 损伤严重性*
第二次后14天   第二次后28天
  相对于对照组的降低 中数n 数量
47006＜400  31574＜400     449＜50     58.3316.67     33.338.33     8.3375.00     37.50587.50     94％-   1.0011.50   510
*感染后4-12天内损伤评分的和(无损伤的动物不考虑)损伤评分：无损伤(0)，阴道损伤(0.5或1)，外部皮肤水疱(2，4，8或16)**初期感染系数＝和数(最大得分i)×(发病率％)；而i＝0，0.5，1，2，4，8或16
该图表显示出在预防模型中，用gD/MPL/QS21/SUV免疫接种诱发了极高水平的对初期病变的预防保护效应。无论是外部损伤发病率还是损伤的严重性在用gD/MPL/QS21/SUV免疫接种的动物组中均有极大程度的降低。2.2.2治疗模型
在该治疗模型中，首先用105pfu HSV-2MS株攻击雌性的Hartloy豚鼠。将带有疱疹损伤的动物再进行随机分组，每组16只。
在第21天和42天，用下列配方之一免疫动物：-gD+MPL50μg+QS21 50μg+含250μg胆固醇的SUV-gD+Al(OH)3+MPL50μg+QS21 50μg+含有250μg胆固醇的SUV或者不处理。
从第22-75天每天监测动物以评估疾病的复发状况。评分如预防模型中所述。结果如下列图表所示：
治疗模型
数量     配方     严重性*     持续时间**     发作病例数***
    中数 相对于对照组所降低的百分数(％)     中数   相以于对照组所降低的百分数(％)     中数   相对于对照组所降低的百分数(％)
    161516 gD+MPL+QS21+SUVgD+Al(OH)3+MPL+QS21+SUV未处理     9.008.5015.75     43％46％-   7.007.008.50     18％18％-     3.003.003.50     14％14％-
*感染后第22-75天的损伤得分的和
**感染后第22-75天，实验动物复发损伤的总天数
***感染后第22-75天的复发发作数例数。发作在先且在随后的一天无损伤，其特征是至少有两天的红斑(得分＝0.5)或者一天的外部水疱(得分＞＝2)免疫治疗在第21天和第42天进行。
该结果表明在HSV-2感染的治疗模型中也能诱导出良好的保护水平。用含或不含明矾的gD/MPL/QS21/SUV免疫对复发疾病的严重性的中位数产生了显著的影响。它也略微降低了发作病例数和持续时间(见表)。

Claims (12)

1.一种含有抗原，免疫活性皂苷组分和固醇的疫苗组合物。
2.根据权利要求1所述的疫苗组合物，其中的免疫性皂苷组分是QS21。
3.根据权利要求1或2所述的疫苗组合物，其中的固醇是胆固醇。
4.根据权利要求2或3所述的疫苗组合物，其中的QS21∶固醇的比率是从1∶100到1∶1。
5.根据权利要求1到4所述的任何一个疫苗组合物，其还含有MPL。
6.一种如上文中所述要求的含有抗原或者抗原组合物的疫苗组合物，该抗原或者抗原组合物来源于人免疫缺陷性病毒，猫科免疫缺陷性病毒，水痘带状疱疹病毒，单疱疹病毒I型，单疱疹病毒II型，人巨细胞症病毒，甲、乙、丙或戊型肝炎病肝，呼吸道合胞病毒，人乳头瘤病毒，流感病毒，Hib，脑膜炎病毒，沙门氏菌，奈瑟菌属，疏螺旋体属，衣原体属，博代杆菌属，疟原虫属或者弓形虫属的任何一种。
7.根据权利要求1到5所述的任何一个疫苗，其中的抗原是一种肿瘤抗原。
8.使用如权利要求1到5所述的任何一个组合物制备用于预防病毒性，细菌性，或者寄生虫性感染的疫苗。
9.使用如权利要求1到5所述的任何一个组合物制备用于免疫治疗病毒性，细菌性，寄生虫性感染或者肿瘤的疫苗。
10.一种医治患病原性感染或易受病原性感染的哺乳动物的方法，其包括给于安全且有效剂量的如权利要求1到5所述的任何一种组合物。
11.一种治疗患癌症的哺乳动物的方法，其包括给于安全且有效剂量的如权利要求1到5所述的任何一种组合物。
12一种制备如权利要求1所述的疫苗组合物的工艺，其包括将免疫活性皂苷组分及胆固醇和抗原或者抗原组合物相混合。
CN96193443A 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗 Expired - Lifetime CN1111071C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9508326.7 1995-04-25
GBGB9508326.7A GB9508326D0 (en) 1995-04-25 1995-04-25 Vaccines
GBGB9513107.4A GB9513107D0 (en) 1995-06-28 1995-06-28 Vaccines
GB9513107.4 1995-06-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNB021529795A Division CN1248737C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗
CNB021529787A Division CN1289065C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗

Publications (2)

Publication Number Publication Date
CN1182370A true CN1182370A (zh) 1998-05-20
CN1111071C CN1111071C (zh) 2003-06-11

Family

ID=26306923

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB021529787A Expired - Lifetime CN1289065C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗
CNB021529795A Expired - Lifetime CN1248737C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗
CN96193443A Expired - Lifetime CN1111071C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CNB021529787A Expired - Lifetime CN1289065C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗
CNB021529795A Expired - Lifetime CN1248737C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗

Country Status (37)

Country Link
EP (3) EP0955059B1 (zh)
JP (1) JP3901731B2 (zh)
KR (1) KR100463372B1 (zh)
CN (3) CN1289065C (zh)
AP (1) AP771A (zh)
AR (1) AR001686A1 (zh)
AT (2) ATE186842T1 (zh)
AU (2) AU693022B2 (zh)
BG (1) BG63491B1 (zh)
BR (1) BR9608199B1 (zh)
CA (1) CA2217178C (zh)
CY (1) CY2588B2 (zh)
CZ (1) CZ296216B6 (zh)
DE (2) DE69637254T2 (zh)
DK (2) DK0955059T3 (zh)
DZ (1) DZ2026A1 (zh)
EA (1) EA000839B1 (zh)
ES (2) ES2140076T5 (zh)
GR (1) GR3031912T3 (zh)
HK (2) HK1009086A1 (zh)
HU (1) HU227944B1 (zh)
IL (1) IL118004A (zh)
MA (1) MA23850A1 (zh)
MY (1) MY134811A (zh)
NO (1) NO322190B1 (zh)
NZ (1) NZ305365A (zh)
OA (1) OA10629A (zh)
PL (1) PL184061B1 (zh)
PT (1) PT955059E (zh)
RO (1) RO119068B1 (zh)
SA (1) SA96170297B1 (zh)
SI (2) SI0955059T1 (zh)
SK (1) SK282017B6 (zh)
TR (1) TR199701252T1 (zh)
TW (1) TW515715B (zh)
UA (1) UA56132C2 (zh)
WO (1) WO1996033739A1 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101208100A (zh) * 2005-06-30 2008-06-25 葛兰素史密丝克莱恩生物有限公司 抗疟疾疫苗
CN102458457A (zh) * 2009-06-10 2012-05-16 葛兰素史密丝克莱恩生物有限公司 包含非离子等渗剂的佐剂组合物
CN103405764A (zh) * 2005-12-13 2013-11-27 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物
CN106456739A (zh) * 2014-04-02 2017-02-22 葛兰素史密丝克莱恩生物有限公司 用于诱导免疫应答的新方法
CN107375921A (zh) * 2017-06-12 2017-11-24 商丘美兰生物工程有限公司 一种甘草皂苷脂质体免疫佐剂及其制备方法
CN108289946A (zh) * 2015-10-19 2018-07-17 卡迪拉保健有限公司 新佐剂和包含所述新佐剂的疫苗组合物

Families Citing this family (488)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
ES2327693T3 (es) * 1997-08-29 2009-11-02 Antigenics Inc. Composiciones que comprenden el adyvante qs-21 y polisorbato o ciclodextrina excipiente.
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69815692T2 (de) * 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EP1584685B1 (en) 1998-02-05 2011-04-13 GlaxoSmithKline Biologicals SA Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP4227302B2 (ja) 1998-04-07 2009-02-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PL346213A1 (en) 1998-08-07 2002-01-28 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CN100558401C (zh) 1998-10-16 2009-11-11 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
ATE469222T1 (de) 1998-12-08 2010-06-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
CA2354028A1 (en) 1998-12-08 2000-06-15 Smithkline Beecham Biologicals S.A. Neisseria meningitidis basb041 polypeptides and encoding polynucleotides and uses thereof
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
EP2204186B1 (en) * 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
ATE451461T1 (de) 1999-03-12 2009-12-15 Glaxosmithkline Biolog Sa Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
JP4846906B2 (ja) * 1999-03-19 2011-12-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
NZ514818A (en) 1999-04-02 2004-04-30 Corixa Corp Compounds and methods for therapy and diagnosis of lung cancer
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
IL145982A0 (en) 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
WO2001041802A1 (en) * 1999-12-08 2001-06-14 Statens Veterinärmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
PL209127B1 (pl) 2000-02-23 2011-07-29 Smithkline Beecham Biolog Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ATE398463T1 (de) * 2000-04-13 2008-07-15 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
ES2276788T3 (es) 2000-05-10 2007-07-01 Sanofi Pasteur Limited Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
JP5139618B2 (ja) 2000-06-20 2013-02-06 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
ATE396265T1 (de) 2000-06-28 2008-06-15 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
ES2385100T3 (es) 2000-06-29 2012-07-18 Smithkline Beecham Biologicals S.A. Composición de vacuna multivalente con dosis reducida de Haemophilus influenzae de tipo B
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
DK2266603T3 (da) 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa Tumorvacciner
DK1326638T3 (da) * 2000-10-18 2008-03-25 Glaxosmithkline Biolog Sa Vacciner mod cancer
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
WO2002058727A2 (en) * 2001-01-26 2002-08-01 Walter Reed Army Institute Of Research Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002067983A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
CA2452382A1 (en) 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
ES2615362T3 (es) 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
WO2003089460A1 (en) 2002-04-19 2003-10-30 The Governing Council Of The University Of Toronto Immunological methods and compositions for the treatment of alzheimer's disease
ATE494907T1 (de) 2002-07-18 2011-01-15 Univ Washington Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
AU2003250204B8 (en) 2002-08-02 2008-07-10 Glaxosmithkline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
PT2353608T (pt) 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
ES2309485T3 (es) 2003-01-06 2008-12-16 Wyeth Composiciones y procedimientos para diagnosticar y tratar los canceres de colon.
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
JP2006515024A (ja) * 2003-01-29 2006-05-18 ファイザー・プロダクツ・インク Ｂｏｒｄｅｔｅｌｌａｂｒｏｎｃｈｉｓｅｐｔｉｃａに対するイヌワクチン
US10272147B2 (en) 2003-01-30 2019-04-30 Glaxosmithkline Biologicals S.A. Injectable vaccines against multiple meningococcal serogroups
CN1767854B (zh) 2003-04-04 2013-07-24 硕腾P有限责任公司 微流化水包油乳剂及疫苗组合物
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
JP4875490B2 (ja) 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
PT1961426E (pt) 2003-10-02 2011-06-28 Novartis Vaccines & Diagnostic Vacinas combinadas contra a meningite
CA2539715C (en) 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
ATE554106T1 (de) 2003-12-23 2012-05-15 Arbor Vita Corp Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
CA2555274A1 (en) 2004-02-05 2005-08-25 The Ohio State University Research Foundation Chimeric vegf peptides
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
PL1742659T3 (pl) * 2004-04-05 2013-08-30 Zoetis Services Llc Poddane mikrofluidyzacji emulsje typu olej w wodzie oraz kompozycje szczepionek
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
PL1740217T3 (pl) 2004-04-30 2012-03-30 Novartis Ag Szczepienie koniugatem meningokokowym
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
WO2006031264A2 (en) 2004-05-25 2006-03-23 Oregon Health And Science University Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
EP1755666B1 (en) * 2004-05-28 2010-12-15 GlaxoSmithKline Biologicals SA Vaccine compositions comprising virosomes and a saponin adjuvant
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
CA2580103C (en) 2004-09-22 2021-11-16 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2808384B1 (en) 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2534752T3 (es) 2004-12-07 2015-04-27 Toray Industries, Inc. Nuevo péptido antigénico contra el cáncer y utilización del mismo
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
DK2351772T3 (en) 2005-02-18 2016-09-05 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TW200722101A (en) 2005-03-23 2007-06-16 Glaxosmithkline Biolog Sa Novel composition
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CA2602637A1 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
NZ562729A (en) 2005-04-29 2009-10-30 Infectious Disease Res Inst Id Novel method for preventing or treating M tuberculosis infection using Mtb72f fusion proteins
AU2006261342B2 (en) 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
WO2007005627A2 (en) 2005-07-01 2007-01-11 Forsyth Dental Infirmary For Children Tuberculosis antigen detection assays and vaccines
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
EA014062B1 (ru) 2005-11-01 2010-08-30 Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DE102005059242A1 (de) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molekulare Marker für eine Tumordiagnose und -therapie
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
LT2384765T (lt) 2005-12-22 2017-01-10 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae vakcina
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
SG175492A1 (en) 2006-01-17 2011-11-28 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
JP6087041B2 (ja) 2006-01-27 2017-03-08 ノバルティス アーゲー 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
PT2004220E (pt) 2006-03-30 2015-09-24 Zoetis Services Llc Métodos e composições para vacinação de aves de capoeira
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
MX2008015372A (es) 2006-06-02 2009-03-23 Glaxosmithkline Biolog Sa Método para identificar si un paciente sera respondedor o no a inmunoterapia.
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
WO2007144316A2 (en) 2006-06-12 2007-12-21 Glaxosmithkline Biologicals Sa Vaccine
RU2450019C2 (ru) 2006-06-29 2012-05-10 Новартис Аг Полипептиды из neisseria meningitidis
SI2043682T1 (sl) 2006-07-17 2014-07-31 Glaxosmithkline Biologicals S.A. Influenčno cepivo
AU2007276219B2 (en) 2006-07-18 2013-10-03 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
AU2007293672B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
CA2663196A1 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2468300T3 (pl) 2006-09-26 2018-04-30 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
CA2669209C (en) * 2006-11-20 2016-01-26 Duecom Ab Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
EP2679240A1 (en) 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2679410C (en) 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
JP5378350B2 (ja) 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
US20100322949A1 (en) 2007-04-26 2010-12-23 Ludwig Institute For Cancer Research Ltd. Methods for diagnosing and treating astrocytomas
AR066376A1 (es) 2007-05-02 2009-08-12 Glaxosmithkline Biolog Sa Vacuna
CA2688284A1 (en) 2007-05-25 2008-12-04 Novartis Ag Streptococcus pneumoniae pilus antigens
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
EA020817B1 (ru) 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010001284A (es) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.
JP2010535504A (ja) 2007-08-03 2010-11-25 プレジデント アンド フェロウズ オブ ハーバード カレッジ クラミジア抗原
CA2695477A1 (en) 2007-08-13 2009-02-19 Glaxosmithkline Biologicals S.A. Infant plasmodium falciparum cs vaccines
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
BRPI0817008A2 (pt) 2007-09-17 2017-05-16 Glaxosmithkline Biologicals Sa oligonucleotídeo, inciador ou sonda, par de iniciadores, kit, métodos para detectar a presença e/ou a quantidade do gene mage-a3 não metilado e metilado em uma amostra a contendo dna, para diagnosticar câncer ou predisposição ao câncer ou predisposição ao câncer, para identificar e/ou selecionar um paciente adequado para tratamento com um imunoterapêutico de mage-a3, para predizer a probabilidade de tratamento bem sucedido do câncer, para selecionar um regime de tratamento adequado para câncer, para tratar câncer em um paciente, para tratar um paciente suscetível á recorrência de um tumor expressando mage-a3, e, uso de uma composição
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
KR101692820B1 (ko) 2007-10-25 2017-01-05 도레이 카부시키가이샤 면역 유도제
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2227250A4 (en) 2007-12-03 2011-07-06 Harvard College ANTIGENS OF CHLAMYDIA
WO2009117035A1 (en) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
RU2498994C2 (ru) 2007-12-21 2013-11-20 Новартис Аг Мутантные формы стрептолизина о
MX2010007107A (es) 2007-12-24 2010-12-21 Id Biomedical Corp Quebec Antigenos de virus del sincicio respiratorio recombinantes.
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
WO2009115917A2 (en) 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
ES2553113T3 (es) 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vacuna
CN102065880B (zh) 2008-04-18 2015-11-25 综合医院公司 使用自我装配疫苗的免疫治疗
US9314515B2 (en) 2008-04-25 2016-04-19 Ludwig Institute For Cancer Research Ltd. Targeted treatment for patients with estrogen receptor negative and progesterone receptor negative breast cancers
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
KR101707569B1 (ko) 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 인플루엔자 백신
DK2324842T3 (da) 2008-08-05 2015-06-22 Toray Industries Immunitetsinducerende middel
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2376089B1 (en) 2008-11-17 2018-03-14 The Regents of the University of Michigan Cancer vaccine compositions and methods of using the same
CN102239253A (zh) 2008-12-03 2011-11-09 普罗蒂亚维仕尼科技有限公司 谷氨酰tRNA合成酶（GtS）片段
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
KR101738704B1 (ko) * 2009-02-17 2017-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 알루미늄-비함유 아주반트를 포함하는 불활성화 뎅기 바이러스 백신
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
KR20110128316A (ko) 2009-02-20 2011-11-29 가니메드 파마슈티칼스 아게 암의 진단 및 치료를 위한 방법 및 조성물
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
WO2010105815A2 (en) 2009-03-17 2010-09-23 Oncomethylome Sciences S.A. Improved detection of gene expression
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
EP2944320A1 (en) 2009-06-15 2015-11-18 National University of Singapore Influenza vaccine, composition, and methods of use
US20100316673A1 (en) 2009-06-16 2010-12-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
US8889146B2 (en) 2009-06-24 2014-11-18 Glaxosmithkline Biologicals, Sa Vaccine
EA023054B1 (ru) 2009-06-24 2016-04-29 Глэксосмитклайн Байолоджикалз С.А. Рекомбинантные антигены pcb
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
EP2453903B1 (en) 2009-07-17 2016-08-17 Industry Academic Cooperation Foundation, Hallym University Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
EP2471801A4 (en) 2009-08-26 2013-12-04 Rna Inc GLYCOLIPIDES DERIVED FROM LIPOTHEICHOIC ACID AND COMPOSITIONS CONTAINING THESE GLYCOLIPIDS
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
US20120283115A1 (en) 2009-08-31 2012-11-08 Ludwig Institute For Cancer Research Ltd. Seromic analysis of ovarian cancer
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
NZ598645A (en) * 2009-09-10 2014-07-25 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
WO2011034950A1 (en) 2009-09-16 2011-03-24 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
WO2011040978A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
KR102126964B1 (ko) 2009-11-11 2020-06-25 가니메드 파마슈티칼스 게엠베하 클라우딘 6 특이적 항체
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
JP2013521327A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP2366709A1 (en) 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
US8840902B2 (en) 2010-03-16 2014-09-23 Biontech Ag Tumor vaccination involving a humoral immune response against self-proteins
SG184188A1 (en) 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127316A1 (en) 2010-04-07 2011-10-13 Novartis Ag Method for generating a parvovirus b19 virus-like particle
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
KR101609032B1 (ko) 2010-06-04 2016-04-04 와이어쓰 엘엘씨 스트렙토코커스 뉴모니아 백신 제제
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN103154242B (zh) 2010-07-06 2015-09-30 诺华股份有限公司 诺如病毒衍生的免疫原性组合物和方法
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
BR122020026648B1 (pt) 2010-09-20 2021-12-07 Biontech Cell & Gene Therapies Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
KR20130140009A (ko) 2010-10-15 2013-12-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 사이토메갈로바이러스 ｇｂ 항원
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
ES2859673T3 (es) 2010-11-08 2021-10-04 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN106822882A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
SI2667892T1 (sl) 2011-01-26 2019-05-31 Glaxosmithkline Biologicals Sa Imunizacijski režim proti RSV
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP2691422B1 (en) 2011-03-29 2019-02-06 UAB Research Foundation Methods and compositions for cytomegalovirus il-10 protein
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
PL3026064T3 (pl) 2011-05-13 2019-05-31 Ganymed Pharmaceuticals Gmbh Przeciwciała do leczenia nowotworu z ekspresją klaudyny 6
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
BR112013029514A2 (pt) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, método de tratar ou impedir uma doença
EP2711015B1 (en) 2011-05-19 2016-06-29 Toray Industries, Inc. Immunity induction agent
KR101949186B1 (ko) 2011-05-19 2019-02-18 도레이 카부시키가이샤 면역 유도제
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
HUE057608T2 (hu) 2011-05-24 2022-06-28 BioNTech SE Individualizált vakcinák a rák ellen
PL3473267T3 (pl) 2011-05-24 2022-01-10 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
WO2013006842A2 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
WO2013016460A1 (en) 2011-07-25 2013-01-31 Novartis Ag Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
US10752676B2 (en) 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
PT2782598T (pt) 2011-11-23 2020-09-02 In3Bio Ltd Codan Services Ltd Proteínas recombinantes e suas utilizações terapêuticas
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
HUE049729T2 (hu) 2011-11-30 2020-10-28 Ludwig Inst For Cancer Res Ltd INKT cella modulátorok és ezek alkalmazásának módszerei
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
EP2811981B1 (en) 2012-02-07 2019-05-08 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
EP3492095A1 (en) 2012-04-01 2019-06-05 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
ES2787455T3 (es) 2012-05-16 2020-10-16 Immune Design Corp Vacunas para el VHS-2
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
RU2659149C2 (ru) 2012-08-03 2018-06-28 Инфекшес Дизиз Рисерч Инститьют Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
WO2014053612A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic composition
JP2016501515A (ja) 2012-10-24 2016-01-21 プレートレット ターゲテッド セラピューティクス，エルエルシー 血小板標的化治療
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
ES2826555T3 (es) 2012-11-30 2021-05-18 Glaxosmithkline Biologicals Sa Antígenos de Pseudomonas y combinación de antígenos
WO2014086787A1 (en) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
UY34506A (es) 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US10058603B2 (en) 2013-03-15 2018-08-28 Glaxosmithkline Biologicals S.A. Vaccine
EP2970409A2 (en) 2013-03-15 2016-01-20 Bioven 3 Limited Self-assembling synthetic proteins
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
KR20160027019A (ko) 2013-06-26 2016-03-09 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 뎅기 바이러스 백신에 대한 방법 및 조성물
EP3777882A1 (en) 2013-07-30 2021-02-17 BioNTech SE Tumor antigens for determining cancer therapy
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
JP6564367B2 (ja) 2013-08-05 2019-08-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP3068426B1 (en) 2013-11-13 2020-02-12 University Of Oslo Outer membrane vesicles and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
US20160287696A1 (en) 2013-11-20 2016-10-06 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
ES2978921T3 (es) 2014-02-20 2024-09-23 Vaxart Inc Formulaciones para administración en el intestino delgado
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
SG10201808315UA (en) 2014-03-25 2018-10-30 The Government Of The Us Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
BE1022744B1 (fr) 2014-03-26 2016-08-29 Glaxosmithkline Biologicals Sa Antigenes staphylococciques mutants
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
BR112016030096B1 (pt) 2014-06-25 2023-10-03 Glaxosmithkline Biologicals S.A Composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
CN106715458A (zh) 2014-07-18 2017-05-24 华盛顿大学 癌症疫苗组合物及其使用方法
WO2016012385A1 (en) 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
EP3212672A4 (en) 2014-11-02 2018-04-25 The University of North Carolina at Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016134300A1 (en) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
WO2016140702A1 (en) 2015-03-03 2016-09-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces Display platform from bacterial spore coat proteins
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
WO2016149771A1 (en) 2015-03-26 2016-09-29 Gamma Vaccines Pty Limited Streptococcal vaccine
MX2017015004A (es) 2015-05-26 2018-07-06 Ohio State Innovation Foundation Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
CN118045170A (zh) 2015-06-12 2024-05-17 瓦克萨特公司 用于rsv和诺如病毒抗原的小肠递送的制剂
EP3138579A1 (en) 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3370730A4 (en) 2015-11-06 2019-07-31 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGS
GB201522132D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Vaccine
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
EP3426289A4 (en) 2016-03-10 2019-08-07 Aperisys, Inc. ANTIGEN-BINDING FUSION PROTEINS WITH MODIFIED HSP70 DOMAINS
MY195541A (en) 2016-03-14 2023-01-31 Univ Oslo Engineered Immunoglobulins With Altered Fcrn Binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
EP3437653A4 (en) 2016-03-28 2019-11-27 Toray Industries, Inc. AGENT INDUCING IMMUNITY
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
EP3458088A2 (en) 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
SG11201900132QA (en) 2016-07-20 2019-02-27 Biontech Rna Pharmaceuticals Gmbh Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
BR112019003462A2 (pt) 2016-08-23 2019-06-25 Glaxosmithkline Biologicals Sa proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
MX2019003035A (es) 2016-09-16 2019-09-13 Infectious Disease Res Inst Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018077385A1 (en) 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3600391A1 (en) 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
CN118085055A (zh) 2017-04-19 2024-05-28 生物医学研究所 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
EP3618836A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENSAPONINALOGA
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) * 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
WO2018229708A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
BR112020001045A2 (pt) 2017-07-18 2020-09-08 In3Bio Ltd. proteínas sintéticas e usos terapêuticos das mesmas
WO2019034575A1 (en) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa METHODS OF AMPLIFYING IMMUNE RESPONSES
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
US11566050B2 (en) 2017-10-18 2023-01-31 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus vaccines and diagnostics
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
EP3747459A4 (en) 2018-02-02 2021-12-01 SL Vaxigen, Inc. NEW VACCINE IMMUNO ADJUVANS
EP3765477A1 (en) 2018-03-15 2021-01-20 BioNTech RNA Pharmaceuticals GmbH 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
CA3102224A1 (en) 2018-06-12 2019-12-19 Glaxosmithkline Biologicals Sa Chimpanzee adenovirus chad157 polynucleotides, polypeptides.vectors, compositions, cells and uses thereof
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
US20210220462A1 (en) 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
US20220118077A1 (en) 2018-09-11 2022-04-21 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US11547672B2 (en) 2018-09-14 2023-01-10 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
WO2020115171A1 (en) 2018-12-06 2020-06-11 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
US11419932B2 (en) 2019-01-24 2022-08-23 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
CA3132601A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
US20220249646A1 (en) 2019-05-25 2022-08-11 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
CA3144845A1 (en) 2019-06-25 2020-12-30 In3Bio Ltd. Stabilized chimeric synthetic proteins and therapeutic uses thereof
MX2022000879A (es) 2019-07-21 2022-05-02 Glaxosmithkline Biologicals Sa Vacuna viral terapeutica.
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN114667158A (zh) 2019-08-05 2022-06-24 葛兰素史克生物有限公司 免疫原性组合物
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
WO2021067785A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V Staphylococcus peptides and methods of use
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
PT4090363T (pt) 2020-01-16 2024-09-19 Janssen Pharmaceuticals Inc Mutante de fimh, composições com o mesmo e sua utilização
CN115175924A (zh) 2020-02-26 2022-10-11 港大科桥有限公司 基于pd-1的针对冠状病毒感染的疫苗
EP4161570A1 (en) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Modified betacoronavirus spike proteins
EP4188427A1 (en) 2020-08-03 2023-06-07 GlaxoSmithKline Biologicals S.A. Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
EP4234585A4 (en) 2020-10-23 2024-10-02 Jiangsu Provincial Center For Disease Control And Prevention Public Health Res Institute Of Jiangsu FUSION PROTEIN AND ITS APPLICATION
MX2023005018A (es) 2020-10-28 2023-05-16 Sanofi Pasteur Liposomas que contienen un agonista de tlr4, preparacion y usos de los mismos.
CA3202549A1 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
EP4277921A1 (en) 2021-01-12 2023-11-22 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
JP2024510717A (ja) 2021-02-22 2024-03-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物、使用及び方法
US20220288181A1 (en) 2021-03-12 2022-09-15 Northwestern University Antiviral vaccines using spherical nucleic acids
EP4313138A1 (en) 2021-03-30 2024-02-07 Viravaxx AG Sars-cov-2 subunit vaccine
US20240156935A1 (en) 2021-03-31 2024-05-16 Vib Vzw Vaccine Compositions for Trypanosomatids
CA3215752A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
BR112023027401A2 (pt) 2021-06-28 2024-03-12 Glaxosmithkline Biologicals Sa Antígenos do vírus influenza
EP4405374A1 (en) 2021-09-23 2024-07-31 Viravaxx AG Hbv vaccine inducing pres-specific neutralizing antibodies
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
WO2023114727A1 (en) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN118695869A (zh) 2022-02-14 2024-09-24 佐治亚大学研究基金会股份有限公司 泛-肺病毒疫苗组合物及其使用方法
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DK0454735T3 (da) * 1989-01-23 1996-10-07 Auspharm Int Ltd Vaccine sammensætning
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
ATE188613T1 (de) * 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
AU676340B2 (en) * 1993-05-25 1997-03-06 Wyeth Holdings Corporation Adjuvants for vaccines against respiratory syncytial virus
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9718901D0 (en) † 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101208100A (zh) * 2005-06-30 2008-06-25 葛兰素史密丝克莱恩生物有限公司 抗疟疾疫苗
CN103405764A (zh) * 2005-12-13 2013-11-27 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物
CN103861100A (zh) * 2005-12-13 2014-06-18 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物
CN102458457A (zh) * 2009-06-10 2012-05-16 葛兰素史密丝克莱恩生物有限公司 包含非离子等渗剂的佐剂组合物
CN102458457B (zh) * 2009-06-10 2015-05-20 葛兰素史密丝克莱恩生物有限公司 包含非离子等渗剂的佐剂组合物
CN106456739A (zh) * 2014-04-02 2017-02-22 葛兰素史密丝克莱恩生物有限公司 用于诱导免疫应答的新方法
CN108289946A (zh) * 2015-10-19 2018-07-17 卡迪拉保健有限公司 新佐剂和包含所述新佐剂的疫苗组合物
CN107375921A (zh) * 2017-06-12 2017-11-24 商丘美兰生物工程有限公司 一种甘草皂苷脂质体免疫佐剂及其制备方法
CN107375921B (zh) * 2017-06-12 2019-10-29 商丘美兰生物工程有限公司 一种甘草皂苷脂质体免疫佐剂及其制备方法

Also Published As

Publication number Publication date
DK0822831T3 (da) 2000-05-01
NO974859L (no) 1997-10-21
CN1480214A (zh) 2004-03-10
SI0955059T1 (sl) 2008-02-29
CN1289065C (zh) 2006-12-13
EA000839B1 (ru) 2000-04-24
KR19990008003A (ko) 1999-01-25
SI0822831T2 (sl) 2006-12-31
NO322190B1 (no) 2006-08-28
CY2588B2 (en) 2009-11-04
DK0822831T4 (da) 2006-12-27
DE69605296T2 (de) 2000-05-18
EP0884056A1 (en) 1998-12-16
PL184061B1 (pl) 2002-08-30
CN1111071C (zh) 2003-06-11
BG63491B1 (bg) 2002-03-29
EP0955059A3 (en) 2000-07-12
IL118004A (en) 1999-11-30
JP3901731B2 (ja) 2007-04-04
ATE186842T1 (de) 1999-12-15
EP0822831B2 (en) 2006-08-23
HUP9801560A3 (en) 1999-07-28
ATE373487T1 (de) 2007-10-15
HUP9801560A1 (hu) 1998-10-28
AP9701123A0 (en) 1997-10-31
NO974859D0 (no) 1997-10-21
SI0822831T1 (en) 2000-02-29
EP0955059B1 (en) 2007-09-19
AU6987398A (en) 1998-07-23
AR001686A1 (es) 1997-11-26
GR3031912T3 (en) 2000-02-29
CA2217178C (en) 2009-09-29
UA56132C2 (uk) 2003-05-15
HK1025244A1 (en) 2000-11-10
EP0822831A1 (en) 1998-02-11
ES2140076T3 (es) 2000-02-16
ES2140076T5 (es) 2007-04-16
CN1515245A (zh) 2004-07-28
EA199700272A1 (ru) 1998-04-30
EP0822831B1 (en) 1999-11-24
PT955059E (pt) 2007-11-27
TR199701252T1 (xx) 1998-03-21
SA96170297B1 (ar) 2005-11-15
DE69605296T3 (de) 2007-02-15
SK144297A3 (en) 1998-05-06
IL118004A0 (en) 1996-08-04
MX9708226A (es) 1998-06-30
DZ2026A1 (fr) 2002-07-21
TW515715B (en) 2003-01-01
AU699213B2 (en) 1998-11-26
SK282017B6 (sk) 2001-10-08
ES2293708T3 (es) 2008-03-16
CZ296216B6 (cs) 2006-02-15
AU693022B2 (en) 1998-06-18
AP771A (en) 1999-10-07
DE69637254D1 (de) 2007-10-31
DE69605296D1 (de) 1999-12-30
HK1009086A1 (en) 1999-05-28
CZ337997A3 (cs) 1998-03-18
HU227944B1 (en) 2012-06-28
EP0955059A2 (en) 1999-11-10
DK0955059T3 (da) 2007-12-17
KR100463372B1 (ko) 2005-02-28
BG101995A (en) 1998-11-30
OA10629A (en) 2002-09-16
MY134811A (en) 2007-12-31
PL322968A1 (en) 1998-03-02
WO1996033739A1 (en) 1996-10-31
BR9608199A (pt) 1999-05-18
NZ305365A (en) 1999-05-28
BR9608199B1 (pt) 2009-05-05
RO119068B1 (ro) 2004-03-30
CA2217178A1 (en) 1996-10-31
JPH11504020A (ja) 1999-04-06
DE69637254T2 (de) 2008-06-19
CN1248737C (zh) 2006-04-05
AU5334596A (en) 1996-11-18
MA23850A1 (fr) 1996-12-31

Similar Documents

Publication Publication Date Title
CN1111071C (zh) 含有皂苷和固醇的疫苗
US6846489B1 (en) Vaccines containing a saponin and a sterol
US5776468A (en) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
AU661404B2 (en) Vaccine composition containing adjuvants
JPH09506887A (ja) ワクチン
AU705739B2 (en) A method of preparing vaccine compositions containing 3-0-deacylated monophosphoryl lipid A
MXPA97008226A (es) Vacunas que contienen una saponina y un esterol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20030611

EXPY Termination of patent right or utility model